Refine by
Tumor Mutation Articles & Analysis
21 news found
Ilkka Haapala’s PhD dissertation explored the possibility of differentiating tumour types and specific mutations based on DMS. We want to congratulate Ilkka on his successful defense of the dissertation at Tampere University on 11.10.2024! IonVision was used as the DMS in several of the studies. The dissertation found that DMS can be used to identify the most common brain tumour ...
SOPHiA GENETICS offers a comprehensive suite of liquid biopsy applications that have helped progress oncology research and tumor mutation profiling. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). ...
Cancer is known to cause by the accumulation of harmful genetic mutations within cells. At present, the research on the mechanism of abnormal cell proliferation, differentiation, and carcinogenesis is mainly divided into three categories: activation of dominant transformation proto-oncogene through translocation and mutation, inactivation of ...
Cancer Vaccine Development Based on pMHC Cancer vaccines to enhance the immune response, target tumor-specific mutations not present in normal tissues, and eradicate tumors. Vaccine Development Based on VLPs with MHC Complex To demonstrate and deliver specific tumor-associated MHC complex antigens and create more scalable and ...
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
The OncoDEEP Kit integrates both reagents and quality control reporting for sequencing over 600 cancer genes and relevant biomarkers, together with OncoDNA’s data analysis and clinical interpretation tools for the rapid analysis and reporting of a patient’s tumor molecular profile. The OncoDEEP Kit has been developed by expert oncologists to contain the most complete ...
Biomarkers have been shown to help identify patients who are most likely to benefit from treatment with immunotherapies, such as PD-1/PD-L1-targeted therapies. Still, the gold standard of tumor tissue PD-L1 staining, as well as other biomarkers, such as tumor mutational burden, do not always accurately predict the efficacy of these therapies in ...
INTEGRATING ONCODEEP IN THEIR PORTFOLIO, SYNLAB LABORATORIES IN GERMANY WILL PERFORM COMPREHENSIVE TESTING OF SOLID TUMORS AND DELIVER DECISION SUPPORT FOR ONCOLOGISTS. THE TECHNOLOGY TRANSFER IS ONGOING, WITH THE OBJECTIVE OF PROCESSING THE FIRST PATIENT SAMPLES EARLY Q2. ...
Emily Hinchcliff (now at Northwestern University Cancer Center), the lead author of the report, noted that based on observations in two exceptional survivors, her team became interested in survival outcomes in patients with inactivating somatic tumor mutations in PPP2R1A, the major scaffold subunit of the protein phosphatase 2A (PP2A) multimeric enzyme. ...
THE OFFER WILL COME IN COMBINATION WITH ONCODNA’S DATA ANALYSIS AND CLINICAL INTERPRETATION TOOLS FOR THE RAPID ANALYSIS AND REPORTING OF A PATIENT’S TUMOR MOLECULAR PROFILE. ONCODEEP KIT IS AVAILABLE FOR EARLY ACCESS AND WILL BE COMMERCIALLY AVAILABLE BY THE END OF Q2 2022. ...
About FoundationOne®CDx FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational ...
The test looks for hundreds of biomarkers in a small amount of tumor tissue, including complex genomic signatures like tumor mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI) that can determine whether immunotherapy or PARP inhibitors would work for a patient. ...
Melanoma is a serious form of skin cancer that accounts for an estimated 207,790 cases each year.1 BRAF mutations are the most common type of mutation in melanoma and are present in more than half of all melanoma cases.2 As a companion diagnostic for therapies targeting BRAFV600E and BRAFV600K mutations in melanoma, FoundationOne®CDx offers ...
Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and genomic alteration status confirmed using an FDA-approved tumor tissue test, if feasible. ...
Orringer—the new approach applies data modalities focused on maximum tumor resection and patient safety to help surgeons make more informed real-time decisions. ...
Seborrheic keratosis (SKs) are benign clonal tumors with activating mutations in the RTK-P13K, Akt, mTOR signaling pathway. SKs affect over 80 million people in the US alone and are frequently seen in middle-aged and older adults. These benign tumors vary in color and can be up to an inch or more wide. They typically have a slightly elevated, ...
Previous research has demonstrated that the LuCED lung test, a non-invasive liquid biopsy sputum assay, has potential to address critical unmet medical needs to advance the lung cancer interception and management in three areas: 1) accurate diagnosis of small and early stage tumors and pulmonary nodules; 2) detection and treatment of pre-cancerous dysplasia; and 3) detection of ...
Thermo Fisher Scientific will host a symposium featuring customer presentations that highlight the latest efforts in tumor mutation burden (TMB) standardization by its European consortium, and clinical research data focused on the application of this emerging biomarker to help guide selection of immunotherapies. ...
This latest version now also extends reporting evidence related to tumor mutation burden, while continuing to maintain high-quality industry reporting standards, such as the multi-tiered system from a joint consensus of the Association for Molecular Pathology, the American Society of Clinical Oncology, and the College of American Pathologists. Scientific ...
Biopharmaceutical Services to Enhance Personalized Medicine: Recent research findings indicate the Cell-CT platform has the potential to detect the presence of specific cancer growth driver mutations entirely through their ‘morphometric’ signatures. Further ongoing research is evaluating the capability to assess cellular level Tumor ...